PDAC Clinical Trials

11 recruiting

PDAC Trials at a Glance

54 actively recruiting trials for pdac are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 1 with 22 trials, with the heaviest enrollment activity in Fairfax, New York, and Boston. Lead sponsors running pdac studies include Revolution Medicines, Inc., Imperial College London, and Azienda Ospedaliera Universitaria Integrata Verona.

Treatments under study

About PDAC Clinical Trials

Looking for clinical trials for PDAC? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PDAC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PDAC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 54 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 2

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE105 enrolled10 locationsNCT07255404
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Not Applicable

Nutrition Intervention for Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neuroendocrine Tumors (pNET)
Children's Hospital of Philadelphia18 enrolled2 locationsNCT07554560
Recruiting
Phase 2

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited39 enrolled1 locationNCT07450859
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma (PDAC)
SOFIE200 enrolled10 locationsNCT07217717
Recruiting
Not Applicable

PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

PDAC - Pancreatic Ductal Adenocarcinoma
Massachusetts General Hospital50 enrolled1 locationNCT07047807
Recruiting
Not Applicable

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neoplasms+1 more
ARTIDIS AG200 enrolled1 locationNCT07542041
Recruiting
Not Applicable

Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)

PDAC - Pancreatic Ductal Adenocarcinoma
IHU Strasbourg60 enrolled2 locationsNCT06666803
Recruiting
Phase 2

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Pancreatic Ductal Adenocarcinoma (PDAC)
Institut Curie35 enrolled1 locationNCT06659705
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1Phase 2

The KN510713 Study in Combination With mFOLFIRINOX

Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
New Cancer Cure-Bio Co.,Ltd.30 enrolled1 locationNCT07114861
Recruiting
Phase 1

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)
University of California, San Diego36 enrolled1 locationNCT06639724
Recruiting
Phase 2

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (mPDAC)
University of California, San Diego43 enrolled1 locationNCT06790602
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.188 enrolled10 locationsNCT06835569
Recruiting

Advanced Therapies for Liver Metastases

Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Liver Metastasis+1 more
IRCCS San Raffaele625 enrolled1 locationNCT04622423
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled2 locationsNCT07491445
Recruiting

Immunoparalysis After Pancreaticoduodenectomy

Pancreatic FistulaPancreatic Ductal Adenocarcinoma (mPDAC)Pancreatic Head Tumour
Hospices Civils de Lyon100 enrolled4 locationsNCT07144917